A Mor1, K Berencsi1, E Svensson1, J Rungby2,3, J S Nielsen4, S Friborg5, I Brandslund6, J S Christiansen7, A Vaag8, H Beck-Nielsen4, H T Sørensen1, R W Thomsen1. 1. Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. 2. Department of Biomedicine, Aarhus University Hospital, Aarhus, Denmark. 3. Center for Diabetes Research, Gentofte University Hospital, Copenhagen, Denmark. 4. Diabetes Research Centre, Department of Endocrinology, Odense University Hospital, Odense, Denmark. 5. Department of Endocrinology, Odense University Hospital, Odense, Denmark. 6. Department of Biochemistry, Lillebaelt Hospital, Vejle, Denmark. 7. Department of Internal Medicine and Endocrinology, Aarhus University Hospital, Aarhus, Denmark. 8. Department of Endocrinology, Rigshospitalet and Copenhagen University, Denmark.
Abstract
AIM: To examine prescribing practices and predictors of glucose-lowering therapy within the first year following diagnosis of Type 2 diabetes mellitus in a clinical care setting. METHODS: We followed people enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort from outpatient hospital clinics and general practices throughout Denmark in 2010-2013. We used Poisson regression to compute age- and gender-adjusted risk ratios (RRs). RESULTS: Among 1158 new Type 2 diabetes mellitus patients, 302 (26%) did not receive glucose-lowering therapy within the first year, 723 (62%) received monotherapy [685 (95%) with metformin], and 133 (12%) received more than one drug. Predictors of receiving any vs. no therapy and combination vs. monotherapy were: age < 40 years [RR: 1.29 (95% CI: 1.16-1.44) and 3.60 (95% CI: 2.36-5.50)]; high Charlson Comorbidity Index [RRs: 1.20 (95% CI: 1.05-1.38) and 2.08 (95% CI: 1.16-3.72)]; central obesity [RRs: 1.23 (95% CI: 1.04-1.44) and 1.93 (95% CI: 0.76-4.94)]; fasting blood glucose of ≥ 7.5 mmol/l [RRs: 1.25 (95% CI: 1.10-1.42) and 1.94 (95% CI: 1.02-3.71)]; and HbA1c ≥ 59 mmol/mol (≥ 7.5%) [RR: 1.26 (95% CI: 1.20-1.32) and 2.86 (95% CI: 1.97-4.14)]. Weight gain ≥ 30 kg since age 20, lack of physical exercise and C-peptide of < 300 pmol/l also predicted therapy. CONCLUSIONS: Comorbidity, young age, central obesity and poor baseline glycaemic control are important predictors of therapy one year after Type 2 diabetes mellitus debut.
AIM: To examine prescribing practices and predictors of glucose-lowering therapy within the first year following diagnosis of Type 2 diabetes mellitus in a clinical care setting. METHODS: We followed people enrolled in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) cohort from outpatient hospital clinics and general practices throughout Denmark in 2010-2013. We used Poisson regression to compute age- and gender-adjusted risk ratios (RRs). RESULTS: Among 1158 new Type 2 diabetes mellituspatients, 302 (26%) did not receive glucose-lowering therapy within the first year, 723 (62%) received monotherapy [685 (95%) with metformin], and 133 (12%) received more than one drug. Predictors of receiving any vs. no therapy and combination vs. monotherapy were: age < 40 years [RR: 1.29 (95% CI: 1.16-1.44) and 3.60 (95% CI: 2.36-5.50)]; high Charlson Comorbidity Index [RRs: 1.20 (95% CI: 1.05-1.38) and 2.08 (95% CI: 1.16-3.72)]; central obesity [RRs: 1.23 (95% CI: 1.04-1.44) and 1.93 (95% CI: 0.76-4.94)]; fasting blood glucose of ≥ 7.5 mmol/l [RRs: 1.25 (95% CI: 1.10-1.42) and 1.94 (95% CI: 1.02-3.71)]; and HbA1c ≥ 59 mmol/mol (≥ 7.5%) [RR: 1.26 (95% CI: 1.20-1.32) and 2.86 (95% CI: 1.97-4.14)]. Weight gain ≥ 30 kg since age 20, lack of physical exercise and C-peptide of < 300 pmol/l also predicted therapy. CONCLUSIONS: Comorbidity, young age, central obesity and poor baseline glycaemic control are important predictors of therapy one year after Type 2 diabetes mellitus debut.
Authors: Megan O Bensignor; Jack M Wolf; Kyle D Rudser; Aaron S Kelly; Silva Arslanian Journal: Diabetes Obes Metab Date: 2022-05-01 Impact factor: 6.408
Authors: S S Kumar; H McManus; T Radovich; J R Greenfield; A Viardot; K M Williams; P Cronin; R O Day Journal: Eur J Clin Pharmacol Date: 2018-06-24 Impact factor: 2.953
Authors: Andrzej Śliwczyński; Melania Brzozowska; Andrzej Jacyna; Petre Iltchev; Tymoteusz Iwańczuk; Waldemar Wierzba; Michał Marczak; Katarzyna Orlewska; Piotr Szymański; Ewa Orlewska Journal: PLoS One Date: 2017-06-05 Impact factor: 3.240